{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:16:13Z","timestamp":1782123373017,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"crossref","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ygyno.2018.08.027","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T13:57:57Z","timestamp":1535723877000},"page":"257-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology\/gynecologic oncology group study"],"prefix":"10.1016","volume":"151","author":[{"given":"William P.","family":"Tew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles Alvarez","family":"Secord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Bonebrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-7000","authenticated-orcid":false,"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2018.08.027_bb0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","article-title":"Markedly elevated levels of vascular endothelial growth factor in malignant ascites","volume":"6","author":"Zebrowski","year":"1999","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.08.027_bb0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1228","article-title":"Prognostic significance of VEGF expression in human ovarian carcinoma","volume":"83","author":"Shen","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2018.08.027_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.1999.5418","article-title":"Serum VEGF in epithelial ovarian neoplasms: correlation with patient survival","volume":"74","author":"Chen","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2018.08.027_bb0020","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2018.08.027_bb0025","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.08.027_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2018.08.027_bb0035","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lawrence","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2018.08.027_bb0040","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockleer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0050","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Gynecology Oncology Group incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0055","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2018.08.027_bb0060","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0065","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"2","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ygyno.2018.08.027_bb0070","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer","volume":"67","author":"Mabunchi","year":"2007","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.ygyno.2018.08.027_bb0075","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabunchi","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2018.08.027_bb0080","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ygyno.2005.12.019","article-title":"Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells","volume":"102","author":"Treeck","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0085","series-title":"Afinitor (Everolimus) Tablets for Oral Administration [Prescribing Information]","year":"2012"},{"issue":"7353","key":"10.1016\/j.ygyno.2018.08.027_bb0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2018.08.027_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of mTOR inhibitor, temsirolimus, and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.08.027_bb0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0105","doi-asserted-by":"crossref","first-page":"145s","DOI":"10.1200\/jco.2006.24.18_suppl.3097","article-title":"Preliminary results of a phase 1 study of bevacizumab in combination with everolimus (RAD001) in patients with advanced solid tumors","volume":"24","author":"Zafar","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2018.08.027_bb0110","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell cancer","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2018.08.027_bb0115","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.18632\/oncotarget.1834","article-title":"Advanced gynecologic malignancies treated with a combination of the VEGF inhibtor bevacizumab and the mTOR inhibitor temsirolimus","volume":"5","author":"Piha-Pail","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2018.08.027_bb0120","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/sim.4780131321","article-title":"Stopping when the experimental regimen does not appear to help","volume":"13","author":"Wieand","year":"1994","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0125","series-title":"Group Sequential Methods With Applications to Clinical Trials","first-page":"49","author":"Jennison","year":"2000"},{"issue":"19","key":"10.1016\/j.ygyno.2018.08.027_bb0130","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2015.65.8153","article-title":"Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: a NRG oncology\/gynecologic oncology group study","volume":"34","author":"Monk","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.08.027_bb0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:39:38Z","timestamp":1758771578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818311570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0090825818311570"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology\/gynecologic oncology group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}